Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HUTCHMED Voluntarily Withdraws Supplemental New Drug Application in China for Fruquintinib
Recommend 4 Positive 7 Negative 8 |
||||
|
||||
|
HUTCHMED (00013.HK) announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) in China for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma and will evaluate a new route forward. Following an additional internal review of the current data package, in light of recent discussions with the National Medical Products Administration of China (NMPA), HUTCHMED has determined that the submission is unlikely to support an approval in China at this time. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
